Channing Laboratory, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Pharmacogenomics. 2009 Aug;10(8):1231-42. doi: 10.2217/pgs.09.86.
To evaluate phenotypic and genetic variables associated with a poor long-term response to inhaled corticosteroid therapy for asthma, based independently on lung function changes or asthma exacerbations.
MATERIALS & METHODS: We tested 17 phenotypic variables and polymorphisms in FCER2 and CRHR1 in 311 children (aged 5-12 years) randomized to a 4-year course of inhaled corticosteroid during the Childhood Asthma Management Program (CAMP).
Predictors of recurrent asthma exacerbations are distinct from predictors of poor lung function response. A history of prior asthma exacerbations, younger age and a higher IgE level (p < 0.05) are associated with recurrent exacerbations. By contrast, lower bronchodilator response to albuterol and the minor alleles of RS242941 in CRHR1 and T2206C in FCER2 (p < 0.05) are associated with poor lung function response. Poor lung function response does not increase the risk of exacerbations and vice versa (p = 0.72).
Genetic and phenotypic predictors of a poor long-term response to inhaled corticosteroids differ markedly depending on definition of outcome (based on exacerbations vs lung function). These findings are important in comparing outcomes of clinical trials and in designing future pharmacogenetic studies.
根据肺功能变化或哮喘恶化的情况,独立评估与吸入皮质类固醇治疗哮喘长期疗效不佳相关的表型和遗传变量。
我们在儿童哮喘管理计划(CAMP)中对 311 名 5-12 岁儿童进行了为期 4 年的吸入皮质类固醇治疗,检测了 17 个表型变量和 FCER2 和 CRHR1 中的多态性。
哮喘恶化的预测因素与肺功能反应不佳的预测因素不同。既往哮喘恶化史、年龄较小和 IgE 水平较高(p<0.05)与哮喘恶化相关。相比之下,沙丁胺醇支气管扩张反应较低以及 CRHR1 中的 RS242941 次要等位基因和 FCER2 中的 T2206C(p<0.05)与肺功能反应不佳相关。肺功能反应不佳不会增加恶化的风险,反之亦然(p=0.72)。
吸入皮质类固醇治疗长期疗效不佳的遗传和表型预测因素因结局定义(基于恶化与肺功能)而异。这些发现对于比较临床试验结果和设计未来的药物遗传学研究非常重要。